financetom
Business
financetom
/
Business
/
Dubai-based Huda Beauty sells fragrance line KAYALI to co-founder and General Atlantic
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Dubai-based Huda Beauty sells fragrance line KAYALI to co-founder and General Atlantic
Feb 17, 2025 6:38 AM

DUBAI (Reuters) - Dubai-based Huda Beauty will sell its popular fragrance brand KAYALI to its co-founder and General Atlantic in a move that allows the beauty company's owners to buy back a stake held by TSG Consumer Partners since 2017, according to a joint statement by the three companies on Monday.

Founded by blogger Huda Kattan and sisters Mona and Alya in 2018, Huda Beauty sells everything from luxury eyelashes to makeup and skincare products. The company has more than 54.2 million followers on Instagram, well ahead of rivals Rare Beauty and Kylie Cosmetics which have 8 million and 24.7 million followers respectively.

"Huda Beauty is making history as one of the few established beauty brands to return to full founder ownership," the statement said.

KAYALI founder Mona Kattan will own the fast-growing fragrance business with private equity investor General Atlantic, the statement said. KAYALI will operate as an independent company and Mona will remain as CEO, it added.

A value for the deal, which is subject to regulatory approval, was not disclosed.

Goldman Sachs International acted as Huda Beauty's financial advisor, and Gibson Dunn served as its legal advisor. Skadden, Arps, Slate, Meagher & Flom served as Mona Kattan's legal advisor.

Raymond James served as General Atlantic's financial advisor, and Latham & Watkins served as its legal advisor.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
CERo Therapeutics Says CER-1236 Gets FDA Orphan Drug Designation in Acute Myeloid Leukemia
CERo Therapeutics Says CER-1236 Gets FDA Orphan Drug Designation in Acute Myeloid Leukemia
Jun 17, 2025
10:42 AM EDT, 06/17/2025 (MT Newswires) -- CERo Therapeutics ( CERO ) said Tuesday that the US Food and Drug Administration has granted orphan drug designation for the company's lead drug candidate CER-1236 as a potential treatment for acute myeloid leukemia, or AML. The company said CER-1236 is currently under phase 1 clinical trials, with a phase 1/1b study evaluating...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study
Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study
Jun 17, 2025
10:42 AM EDT, 06/17/2025 (MT Newswires) -- Ventyx Biosciences ( VTYX ) shares were down 17% in recent trading Tuesday after topline data from its phase 2a study of its drug candidate VTX3232 in patients with early-stage Parkinson's disease showed Tier 2 exploratory brain-related biomarkers remained unchanged or fluctuated within normal levels. The study achieved its primary safety and tolerability...
AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes
AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes
Jun 17, 2025
AbbVie Inc ( ABBV ) on Monday announced an update from the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS). MDS is a group of cancers in which the bone marrow doesn’t produce enough healthy blood cells. The primary outcome measure is overall survival (OS). Key secondary outcome measures include...
Copyright 2023-2026 - www.financetom.com All Rights Reserved